154 related articles for article (PubMed ID: 8607901)
1. The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation.
Nickerson-Nutter CL; Medvedeff ED
Arthritis Rheum; 1996 Mar; 39(3):515-21. PubMed ID: 8607901
[TBL] [Abstract][Full Text] [Related]
2. Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis.
Anderson GD; Keys KL; De Ciechi PA; Masferrer JL
Inflamm Res; 2009 Feb; 58(2):109-17. PubMed ID: 19184362
[TBL] [Abstract][Full Text] [Related]
3. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
McMillan RM; Spruce KE; Crawley GC; Walker ER; Foster SJ
Br J Pharmacol; 1992 Dec; 107(4):1042-7. PubMed ID: 1334748
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse.
Cunningham FM; Andrews M; Landoni MF; Lees P
J Vet Pharmacol Ther; 1997 Aug; 20(4):296-307. PubMed ID: 9280370
[TBL] [Abstract][Full Text] [Related]
5. Antiedematous effects of combination therapies with the leukotriene synthesis inhibitor BAY X 1005 in the archidonic acid-induced mouse ear inflammation test.
Burchardt ER; Müller-Peddinghaus R
Prostaglandins Leukot Essent Fatty Acids; 1997 Apr; 56(4):301-6. PubMed ID: 9150376
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation.
Kirchner T; Argentieri DC; Barbone AG; Singer M; Steber M; Ansell J; Beers SA; Wachter MP; Wu W; Malloy E; Stewart A; Ritchie DM
J Pharmacol Exp Ther; 1997 Aug; 282(2):1094-101. PubMed ID: 9262379
[TBL] [Abstract][Full Text] [Related]
7. Potential anti-inflammatory effects of 5-lipoxygenase inhibition--exemplified by the leukotriene synthesis inhibitor BAY X 1005.
Müller-Peddinghaus R
J Physiol Pharmacol; 1997 Dec; 48(4):529-36. PubMed ID: 9444606
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of BAY y 1015 in dextran sulfate model of mouse colitis.
Murthy S; Murthy NS; Coppola D; Wood DL
Inflamm Res; 1997 Jun; 46(6):224-33. PubMed ID: 9243306
[TBL] [Abstract][Full Text] [Related]
9. WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity.
Grimes D; Sturm RJ; Marinari LR; Carlson RP; Berkenkopf JW; Musser JH; Kreft AF; Weichman BM
Eur J Pharmacol; 1993 May; 236(2):217-28. PubMed ID: 8391458
[TBL] [Abstract][Full Text] [Related]
10. Phorbol ester-induced dermal inflammation in mice: evaluation of inhibitors of 5-lipoxygenase and antagonists of leukotriene B4 receptor.
Rao TS; Yu SS; Djuric SW; Isakson PC
J Lipid Mediat Cell Signal; 1994 Sep; 10(3):213-28. PubMed ID: 7812673
[TBL] [Abstract][Full Text] [Related]
11. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis.
Weinblatt ME; Kremer JM; Coblyn JS; Helfgott S; Maier AL; Petrillo G; Henson B; Rubin P; Sperling R
J Rheumatol; 1992 Oct; 19(10):1537-41. PubMed ID: 1334515
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton.
Rao NL; Dunford PJ; Xue X; Jiang X; Lundeen KA; Coles F; Riley JP; Williams KN; Grice CA; Edwards JP; Karlsson L; Fourie AM
J Pharmacol Exp Ther; 2007 Jun; 321(3):1154-60. PubMed ID: 17371808
[TBL] [Abstract][Full Text] [Related]
13. A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
Zweifel BS; Hardy MM; Anderson GD; Dufield DR; Pufahl RA; Masferrer JL
Eur J Pharmacol; 2008 Apr; 584(1):166-74. PubMed ID: 18295198
[TBL] [Abstract][Full Text] [Related]
14. The pharmacologic effects of 5-[3,5-bis(1,1-dimethylethyl)-4- hydroxyphenyl]-1,3,4-thiadiazole-2(3H)-thione, choline salt (CI-986), a novel inhibitor of arachidonic acid metabolism in models of inflammation, analgesia and gastric irritation.
Schrier DJ; Baragi VM; Connor DT; Dyer RD; Jordan JH; Imre KM; Lesch ME; Mullican MD; Okonkwo GC; Conroy MC
Prostaglandins; 1994 Jan; 47(1):17-30. PubMed ID: 8140259
[TBL] [Abstract][Full Text] [Related]
15. The effect of a selective 5-lipoxygenase inhibitor, zileuton, on tissue damage in acute colonic inflammation in rats.
Zarif A; Eiznhamer D; Callaghan C; Doria MI; Broutman L; Keshavarzian A
Inflammation; 1996 Jun; 20(3):217-27. PubMed ID: 8796377
[TBL] [Abstract][Full Text] [Related]
16. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis.
Fruchtmann R; Mohrs KH; Hatzelmann A; Raddatz S; Fugmann B; Junge B; Horstmann H; Müller-Peddinghaus R
Agents Actions; 1993 Mar; 38(3-4):188-95. PubMed ID: 8213345
[TBL] [Abstract][Full Text] [Related]
17. Effects of the second-generation leukotriene B(4) receptor antagonist, LY293111Na, on leukocyte infiltration and collagen-induced arthritis in mice.
Kuwabara K; Yasui K; Jyoyama H; Maruyama T; Fleisch JH; Hori Y
Eur J Pharmacol; 2000 Aug; 402(3):275-85. PubMed ID: 10958895
[TBL] [Abstract][Full Text] [Related]
18. Effects of petrosaspongiolide M, a novel phospholipase A2 inhibitor, on acute and chronic inflammation.
Garcia-Pastor P; Randazzo A; Gomez-Paloma L; Alcaraz MJ; Paya M
J Pharmacol Exp Ther; 1999 Apr; 289(1):166-72. PubMed ID: 10087000
[TBL] [Abstract][Full Text] [Related]
19. Involvement of leukotriene B4 in zymosan-induced rat pleurisy: inhibition of leukocyte infiltration by the 5-lipoxygenase inhibitor T-0757.
Kikuchi M; Tsuzurahara K; Naito K
Biol Pharm Bull; 1995 Sep; 18(9):1302-4. PubMed ID: 8845830
[TBL] [Abstract][Full Text] [Related]
20. Blockade of leukotriene B4 prevents articular incapacitation in rat zymosan-induced arthritis.
da Rocha FA; Teixeira MM; Rocha JC; Girão VC; Bezerra MM; Ribeiro Rde A; Cunha Fde Q
Eur J Pharmacol; 2004 Aug; 497(1):81-6. PubMed ID: 15321738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
